Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection
Janssen-Cilag International N.V.
Chronic Plaque Psoriasis
1 trial -
Endoscopic submucosal dissection
United Therapeutics Europe Ltd
Colorectal Neoplasms
1 trial -
Endoscopic submucosal dissection
Chinese University of Hong Kong
Colorectal Neoplasms
1 trial -
Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.
Lacuna Pharma Pty Ltd
Bipolar I Disorder
1 trial -
Enema transplant of fecal microbiota, Placebo Enema transplant of fecal microbiota
Pari Pharma GmbH
Adult patients with ulcerative colitis diagnosed for at least 3 months
1 trial -
Entecavir
Hoffmann-La Roche
Pediatric Immuno-Tolerant Chronic Hepatitis B
1 trial -
Enzastaurin
AYTU BIOPHARMA, INC
Vascular Ehlers-Danlos Syndrome
1 trial -
Epcoritamab (GEN3013), Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Epcoritamab (GEN3013), Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion
AbbVie Deutschland GmbH & Co. KG
Relapsed and Refractory Follicular Lymphoma
1 trial -
Epidyolex 100 mg/ml oral solution
Lacuna Pharma Pty Ltd
Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome
1 trial -
Epinephrine
Chinese University of Hong Kong
Gastric Neoplasm
1 trial -
Epirubicin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).
Lacuna Pharma Pty Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB
Janssen-Cilag International N.V.
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer
1 trial -
Erenumab, Placebo for AMG 334
Amgen
Episodic Migraine
1 trial -
Eribulin Mesylate
United Therapeutics Europe Ltd
Breast Adenocarcinoma
1 trial -
EryDex System
Quince Therapeutics
Ataxia Telangiectasia
1 trial -
Erythropoiesis-Stimulating Agent (ESA)
Akebia Europe Limited
Anemia of Chronic Kidney Disease
1 trial -
EscharEx, Placebo (Gel Vehicle), Amnion/Chorion Membrane Allograft
MediWound Germany GmbH
Venous leg ulcer
1 trial -
Esketamine
Janssen Cilag International NV
Depressive Disorder, Major
1 trial -
Eslicarbazepine acetate (BIA 2-093)
Bial Portela & Companhia S.A.
Partial Epilepsy in Children and Adolescents
1 trial -
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Bayer HealthCare AG
Primary Dysmenorrhea
1 trial -
Etanercept
Coherus Oncology
Plaque Psoriasis
1 trial -
Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg
NovoThirteen
sickle cell disease (SCD)
1 trial -
Etavopivat A 200 mg
NovoThirteen
Sickle Cell Disease and Thalassaemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources